Use of humanized severe combined immunodeficient mice for human vaccine development.
about
Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence researchComparison of hematopoietic stem cells derived from fresh and cryopreserved whole cord blood in the generation of humanized mice.Is human cell therapy research caught in a mousetrap?Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2-/- IL-2Rγ-/- mice: a promising model for studying human disease.Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.New take on comparative immunology: relevance to immunotherapy.Human IDO-competent, long-lived immunoregulatory dendritic cells induced by intracellular pathogen, and their fate in humanized miceTumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.Drug discovery in prostate cancer mouse models.Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Boosting of post-exposure human T-cell and B-cell recall responses in vivo by Burkholderia pseudomallei-related proteins.Human responses against HER-2-positive cancer cells in human immune system-engrafted mice.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.Facial vein injection of human cells in severe combined immunodeficiency (SCID) neonatal miceAdvanced model systems and tools for basic and translational human immunology
P2860
Q28077662-F9A78C23-0F5D-4D14-A0BF-FA17C2FB5400Q34447462-EB7A3FE0-8DBB-4C50-88B4-50C2188B1CA8Q34556966-B7D96F57-6C60-4E37-AB77-755D8BC220D7Q35201052-52F04FE5-4E42-40D4-95B0-CA6A606EF13DQ35634016-4F7F39F8-BC43-42A1-8E1F-0A3E0D9BEBDEQ35812085-0D0EE9AC-5597-4DCF-9ABA-88C5615460F9Q36126352-36A82F98-23E4-48A2-B11F-1A55E4F3885DQ37642581-1F21B636-F243-4958-ACA3-42C6362449D7Q37666685-77A023B9-F19E-4F69-965A-E8FE50B4FEAFQ38509211-C831168C-5C0D-41CF-BCC9-DAE06721DB1AQ38707896-7EC3E41A-A038-4D97-A163-A44B9276BD0BQ38773109-AFEA9E87-C1AE-49BD-8FDC-7C26665141DBQ39289206-0D724B5C-74E1-4055-B45F-F6B6E744E3C8Q52691571-F7A7B9C1-2CC8-44EA-9FFF-D87D26522390Q58581538-64C9AECC-2B3F-4AEF-AA6D-B6879E7EF731Q59126043-1A8F6EA7-523A-4E67-8015-CA88E0AC60E9
P2860
Use of humanized severe combined immunodeficient mice for human vaccine development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of humanized severe combined immunodeficient mice for human vaccine development.
@en
Use of humanized severe combined immunodeficient mice for human vaccine development.
@nl
type
label
Use of humanized severe combined immunodeficient mice for human vaccine development.
@en
Use of humanized severe combined immunodeficient mice for human vaccine development.
@nl
prefLabel
Use of humanized severe combined immunodeficient mice for human vaccine development.
@en
Use of humanized severe combined immunodeficient mice for human vaccine development.
@nl
P2093
P2860
P356
P1476
Use of humanized severe combined immunodeficient mice for human vaccine development.
@en
P2093
Aisha Hasan
Gloria C Koo
Richard J O'Reilly
P2860
P304
P356
10.1586/14760584.8.1.113
P50
P577
2009-01-01T00:00:00Z